Proskauer Reps Grifols In $3.4B Talecris Buy
Spanish health care company Grifols SA announced Monday that it had agreed to purchase Talecris Biotherapeutics for approximately $3.4 billion, nearly a year after a previous buyer for the Cerberus Capital...To view the full article, register now.
Already a subscriber? Click here to view full article